Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
21.40
+1.10 (+5.42%)
Streaming Delayed Price
Updated: 12:24 PM EDT, Aug 15, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
July 28, 2025
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Retail Bulls Stick With Sarepta After 8-Year-Old Patient’s Death Deemed Unrelated To DMD Gene Therapy
July 28, 2025
The update comes as Sarepta faces mounting regulatory scrutiny, including an ongoing FDA investigation and a recommendation from European regulators to reject approval of Elevidys.
Via
Stocktwits
Topics
Death
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
July 25, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
July 25, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement
July 23, 2025
Via
Stocktwits
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy
July 25, 2025
Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.
Via
Benzinga
Sarepta Stock Slumps After EU Regulator Recommends Refusing Approval To Its Contentious Gene Therapy: Retail Expects Stock Bounceback
July 25, 2025
Roche announced on Friday that it plans to continue working with the EMA to explore a potential path forward.
Via
Stocktwits
Topics
Death
Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe
July 25, 2025
Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys.
Via
Investor's Business Daily
Topics
Death
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
July 25, 2025
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
July 25, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session
July 25, 2025
Via
Benzinga
Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union
July 25, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Friday's pre-market session: top gainers and losers
July 25, 2025
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
July 25, 2025
Via
Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm
July 24, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies.
July 24, 2025
Sarepta stock is now trading at a nine-year low as the debacle with its gene therapy, Elevidys, continues.
Via
Investor's Business Daily
Topics
Death
Workforce
12 Health Care Stocks Moving In Thursday's Intraday Session
July 24, 2025
Via
Benzinga
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
July 24, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
July 24, 2025
Via
TheNewswire.com
Topics
Fraud
Lawsuit
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
July 24, 2025
Via
Benzinga
Is This Stock a Buy After Soaring by 20% in 1 Day?
July 24, 2025
Via
The Motley Fool
Topics
Death
Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label
July 23, 2025
Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and valuation cuts.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
July 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc. (SRPT) Shareholders
July 23, 2025
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc. (SRPT) Shareholders
July 23, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division
July 22, 2025
George Tidmarsh appointed to lead FDA drug review division amid staffing cuts and scrutiny over accelerated approvals and drug advertising rules.
Via
Benzinga
Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
July 22, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
July 22, 2025
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Sarepta Tumbles On The 'Painful' Decision To Stop Selling Elevidys
July 22, 2025
Sarepta stock toppled Tuesday after the company said it would voluntarily stop all shipments of Elevidys.
Via
Investor's Business Daily
Topics
Death
ETFs
Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review
July 22, 2025
Sarepta pauses U.S. Elevidys shipments to complete FDA-requested safety label updates, aiming to resume distribution in the fourth quarter.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.